Sort   by:  
 Page size 
UnknownBruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Not available
S-EPMC5505166 | biostudies-literature
UnknownMonitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.
Not available
S-EPMC8630614 | biostudies-literature
UnknownSingle-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Not available
S-EPMC5921964 | biostudies-literature
UnknownExtended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Not available
S-EPMC6317338 | biostudies-literature
UnknownComprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samples.
Not available
S-EPMC12495756 | biostudies-literature
UnknownPhase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Not available
S-EPMC6706803 | biostudies-literature
UnknownVenetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Not available
S-EPMC5922273 | biostudies-literature
UnknownIdelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.
Not available
S-EPMC6745995 | biostudies-literature
UnknownXPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.
Not available
S-EPMC10758694 | biostudies-literature
UnknownCombinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
Not available
S-EPMC4957280 | biostudies-literature
Sort   by:  
 Page size